Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysisBarbara Schormair, Bertram Müller‐Myhsok, Chen Zhao et al.|The Lancet Neurology|2017Cited by 244
Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extensionClaudia Trenkwalder, Ralf Kohnen, K. Reimer et al.|The Lancet Neurology|2013Cited by 227
Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1Juliane Winkelmann, Paul E. Peppard, Darina Czamara et al.|PLoS Genetics|2011Cited by 197
Correction: Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1Juliane Winkelmann, Paul E. Peppard, Darina Czamara et al.|PLoS Genetics|2011Cited by 16